Current treatment status-Undergoing active treatment-Progressive despite treatment - Page 12 of 29 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Allogenic hematopoietic stem cell transplant for patients with unresponsive acute myeloid leukemia

Allogenic hematopoietic stem cell transplant for patients with unresponsive acute myeloid leukemia

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of allogeneic hemopoietic stem cell transplant (alloHSCT) in patients with unresponsive acute myeloid leukemia. This study concluded that alloHSCT is the best treatment option for these patients. Some background Patients with unresponsive acute myeloid leukemia (AML) are those...

Read More

Searching for patients to try a new therapy for non-responsive leukemia/lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Leukemia | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive leukemia/lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with...

Read More

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...

Read More

Looking for patients with relapsed or unresponsive lymphoma to test a cell therapy

Looking for patients with relapsed or unresponsive lymphoma to test a cell therapy

Posted by on Mar 4, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma

Combining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients.  Some background Mantle cell...

Read More

Looking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment

Looking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...

Read More

Looking for patients with relapse/unresponsive lymphoma to test a treatment combination

Looking for patients with relapse/unresponsive lymphoma to test a treatment combination

Posted by on Feb 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...

Read More

Looking for patients with relapsed or refractory lymphoma to test a cell therapy

Looking for patients with relapsed or refractory lymphoma to test a cell therapy

Posted by on Feb 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...

Read More

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More